Alzheimer Disease, Late Onset
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Logistic regression models adjusted by age, sex, and APOE were used to calculate risk associations between methylation levels and LOAD.
|
31335457 |
2020 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
All patterns, except the superior parietal pattern, were influenced by apolipoprotein E. Our step-wise approach revealed atrophy patterns that partially resembled imaging findings in early stages of AD.
|
31402375 |
2020 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
This suggests that APOE-ε4-related vascular factors are also part of the pathway to AD pathology, in synergy with an elevated immune response, and could become targets for trials focused on delaying AD.
|
31733942 |
2020 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we report that common single nucleotide polymorphism (SNP) variation in BACE2 is associated with altered AD risk in apolipoprotein E gene (APOE) epsilon 4 variant (ε4) non-carriers.
|
31270419 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies indicate that the possession of two apoE4 alleles is a strong genetic risk factor for late-onset Alzheimer's disease (LOAD).
|
30933499 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fifteen percent of the associations between non-APOE LOAD risk loci and cognition were significant.
|
31156182 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
APOE, MTHFR A1298C and BDNF C270T polymorphisms may be associated with LOAD and BDNF and MTHFR alleles may play a role in the age at onset of the LOAD.
|
31102717 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified 31 articles which suggested that APOE genotyping for LOAD susceptibility provides potential benefits to at-risk patients and can guide changes in positive health-related behaviors.
|
30382407 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Late-onset Alzheimer's disease is multifactorial and associated with many different genetic risk loci (>20), with the apolipoprotein E ε4 allele being a major genetic risk factor for late-onset Alzheimer's disease.
|
31705489 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic studies indicate that most of the risk of developing late onset Alzheimer's disease, the most common form of the disease, affecting patients aged 65 years and older, is associated with genes (ie, APOE, APOJ, and SORL) that are mainly expressed by glial cells (ie, astrocytes, microglia, and oligodendrocytes).
|
30795987 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A better understanding of apoE isoform-specific interaction with their metabolic receptor LRP1 on Aβ metabolism is crucial for defining APOE4-related risk for AD.
|
30741718 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
These differences suggest that lipoprotein assembly or stability in AD brain plays an important role in determining apoE4 pathogenicity.
|
30581971 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E (APOE) is a susceptibility gene for late-onset Alzheimer's disease neuropathology; less is known about the relationship between APOE and cerebrovascular disease (CVD) neuropathology.
|
30321502 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, in the subgroup analysis carried out using APOE ɛ4 status, a substantial increase in the susceptibility to LOAD was detected in APOE ɛ4 carriers as well as non-APOE ɛ4 carriers.
|
30631824 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to identify the associated genes involved in LOAD not-carrying APOE4.
|
31441725 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Background Apolipoprotein E4 (APOE4) is a major genetic risk factor for late-onset Alzheimer disease.
|
31012816 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review discusses recent advances in understanding the different functions of APOE in the periphery and in the brain, and highlights several promising APOE-targeted therapeutic strategies for AD.
|
31181302 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Definition of Late Onset Alzheimer's Disease and Anticipation Effect of Genome-Wide Significant Risk Variants: Pilot Study of the APOE e4 Allele.
|
30110694 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To identify rare variants possibly explaining part of the genetic architecture for LOAD in Japanese people, we performed whole-exome sequencing analyses of 202 LOAD individuals without the APOE ε4 risk allele, a major genetic factor for LOAD susceptibility.
|
31216982 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, self-assembly of the ApoE4 isoform may play a role in pathogenesis, and these results open opportunities for uncovering new triggers for AD onset.
|
31051176 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data identify a novel gene-regulatory pathway involving CXorf56 that may link apoE4 to microglia activation and inflammation associated with AD.
|
31198491 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, these new knock-in strains offer a novel and dynamic tool to study the role of APOE in AD pathogenesis in a spatially and temporally controlled manner.
|
31623648 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
The gene APOE is associated with cognitive change and late-onset Alzheimer's disease, and epidemiological studies have provided strong evidence that the e<sub>2</sub> allele of APOE has a neuroprotective effect, it is associated with increased longevity and an extended healthy lifespan in centenarians.
|
31385390 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the known LOAD risk factor, APOE was included in this study to test whether any BER gene variants associate with APOE variants, particularly APOE ε4.
|
31415677 |
2019 |
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results support apoE4-related early-life plasticity impairments that precede the AD clinical manifestations and affect any brain area that depends on extensive plasticity; early impairments that may promote the development of AD pathologies later in life.
|
31561365 |
2019 |